<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771676</url>
  </required_header>
  <id_info>
    <org_study_id>2012229-11</org_study_id>
    <nct_id>NCT04771676</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites</brief_title>
  <official_title>A Phase II Study of Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of effectiveness and local immune activation of Oncolytic Viruses H101 in patients&#xD;
      with refractory malignant ascites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate the effectiveness of local immune activation, and safety in&#xD;
      patients with refractory malignant ascites after Intraperitoneal injection of oncolytic&#xD;
      Viruses H101.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>at four weeks after injection</time_frame>
    <description>The objective response rate (ORR) was calculated as a summed ratio of patients with disappeared and decreased ascites to the total number of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline local immune effects after H101 intraperitoneal injections</measure>
    <time_frame>at baseline, 3-, 7, 14 days after injection</time_frame>
    <description>Detection of increased local immune activation in malignant ascites will be assessed by single cell sequencing and Mass Cytometry (CyTOF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic immune response</measure>
    <time_frame>at baseline, 3-, 7, 14 days after injection</time_frame>
    <description>Detection of increased systemic immune Response markers in peripheral blood mononuclear cells by CyTOF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of adverse events</measure>
    <time_frame>At day 3, 7 and 14</time_frame>
    <description>Toxicity were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.&#xD;
All serious and non-serious adverse events that occur after enrollment through 30 (+7) days after the last administration of H101 will be recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Refractory Malignant Ascites</condition>
  <arm_group>
    <arm_group_label>Oncorine (H101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H101 diluted in 5ml 0.9% sodium chloride solution in was then intraperitoneally injected through the drainage catheter, the injection dose of H101 was determined by the ascites volume [5.0×10^11 vp for a small amount, 1×10^12 vp - 1.5×10^12 vp for medium amount, and 2×10^12 vp for the massive amount (classification of the ascites amount was described in response evaluation)]. H101 was injected at day 1 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oncorine (H101)</intervention_name>
    <description>A modified human recombinant type 5 adenovirus with genetic modifications.</description>
    <arm_group_label>Oncorine (H101)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
          -  Age ≥ 18 years at time of study entry.&#xD;
&#xD;
          -  Cytologically diagnosed solid tumor malignancy.&#xD;
&#xD;
          -  Malignant peritoneal ascites confirmed by peritoneal brush cytology.&#xD;
&#xD;
          -  Failures from chemotherapy against malignant ascites.&#xD;
&#xD;
          -  Cooperative Oncology Group-Status (ECOG Status) 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or evidence of active autoimmune disease that requires systemic treatment.&#xD;
&#xD;
          -  Acute or chronic active Hepatitis B or C infection or HIV infection.&#xD;
&#xD;
          -  Previous (&lt;4 weeks) or concurrent treatment with systemic or intraperitoneal&#xD;
             chemotherapy or biological agents such as monoclonal antibodies.&#xD;
&#xD;
          -  Concurrent severe illness such as active infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Wang, MD</last_name>
    <phone>86-21-64175590</phone>
    <email>wangp413@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Wang, MD</last_name>
      <phone>86-21-64175590</phone>
      <email>wangp413@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Peng Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

